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Abstract	
Since	 its	 discovery	 in	 1989,	 there	 has	 been	 extensive	 research	 on	 endothelin	 (ET)-1	
physiology,	 as	 well	 as	 pathology.	 Accordingly,	 there	 is	 considerable	 research	 on	 the	
discovery	 of	 therapeutics	 based	 around	 ET-1,	 amongst	 which	 current	 treatment	 options	
include	 endothelin	 receptor	 antagonists.	 These	 target	 the	 ET-1	 receptors,	 which	 are	 G-
protein–coupled	 receptors	 (GPCRs).	 	 We	 have	 effectively	 developed	 a	 soluble	 form	 of	 a	
GPCR	 that	 binds	 to	 ligands,	 by	 constructing	 a	 fusion	 polypeptide	 of	 different	 endothelin	
receptor	 ligand	binding	domains.	Phage	experiments	 identified	strong	binders	to	ET-1.	We	
then	constructed	Fc-fusions	of	the	top	binders	and	further	binding	assays	revealed	a	KD	of	
21.2	 nM	 for	 the	 Fc-ETtr1	 construct	 and	 KD	 of	 77.3	 nM	 for	 the	 Fc-	 ETtr2	 construct.	 These	
constructs	are	soluble	and	have	the	ability	to	bind	and	potentially	sequester	elevated	ET-1	
levels	 that	 are	 prevalent	 in	 different	 diseases.	 These	 results	 provide	 a	 novel	 approach	 to	
targeting	 GPCR–binding	 ligands,	 and	 thereby	 to	 contribute	 to	 a	 very	 important	 class	 of	
therapeutics.		
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Abbreviations	
ECL	 	 	 extracellular	loop	
ET-1	 	 	 endothelin-1	
ETA	 	 	 endothelin	A	
ETB	 	 	 endothelin	B	
ETtr	 	 	 endothelin-1	traps	
FFP	 	 	 Fc-fusion	protein	
GPCR	 	 	 G-protein	-coupled	receptor	
HA	epitope	 	 human	influenza	hemagglutinin	epitope			
LBD	 	 	 ligand	binding	domain	
PBST	 	 	 phosphate	buffered	saline	tween	
SB	 	 	 super	broth	medium	
STR	 	 	 streptavidin	
	
	
Introduction	
Endothelins	 are	 a	 family	 of	 vasoactive	 peptides	 that	 have	 key	 physiological	 functions	 in	
normal	 tissue,	 acting	 as	 modulators	 of	 the	 vascular	 tone,	 tissue	 differentiation,	 cell	
proliferation,	 development	 and	 hormone	 production	 [1].	 The	 family	 of	 endothelins	
comprises	 three	 isoforms	 each	 of	 21	 amino	 acids	 (ET-1,	 ET-2,	 ET-3).	 ET-1	 is	 the	 most	
abundant	member	of	the	family	of	endothelins	[2].	
ET-1	exerts	its	effects	by	binding	to	the	endothelin	A	(ETA)	and	endothelin	B	(ETB)	receptors,	
two	highly	homologous	cell-surface	proteins	that	belong	to	the	G-protein-coupled	receptor	
superfamily	[3].	The	two	receptors	share	about	60%	similarity	 in	the	primary	structure	[1].	
The	ETA	receptor	shows	different	affinities	to	the	three	endothelin	isoforms	in	the	order	ET-
1	≥	ET-2	>	>	ET-3	 [4],	while	 the	ETB	receptor	binds	 to	ET-1,	ET-2	and	ET-3	with	an	almost	
equal	affinity	[5].		
Previous	 studies	 have	 described	 different	 ET	 receptor	 antagonists,	 which	 compete	 with	
endothelins	 for	binding	 to	 its	 receptors	and	block	G-protein–mediated	signal	 transduction	
[4].	 The	 ET	 receptor	 antagonists	 include	 ETA	 receptor–specific	 and	 ETB	 receptor–specific	
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antagonists,	as	well	as	dual	receptor	antagonists,	such	as	Bosentan.	Needless	to	say,	given	
the	 relevance	 of	 ET-1	 to	 different	 disease	 pathologies,	 these	 antagonists	 have	 important	
therapeutic	value.	Indeed,	some	of	these	are	already	in	clinical	use	[6,	7].	
In	 addition,	 studies	 using	 ET	 antagonists	 have	 helped	 delineate	 the	 mechanism	 of	 ET-1	
(ligand)	binding	to	its	receptors.	For	example,	BQ123	is	a	novel	cyclic	pentapeptide,	cyclo(-
D-Trp-D-Asp-L-Pro-D-Val-L-Leu-),	which	binds	to	the	ET-1–selective	ETA	receptor	but	not	to	
the	 ETB	 receptor	 that	 binds	 ligands	 non-selectively	 [8].	 Studies	with	 this	 antagonist	 have	
helped	identify	the	B-loop	domain	of	the	ETA	receptor	as	important	for	ligand	binding	[4],		a	
conclusion	based	on	the	observation	that	grafting	the	B-loop	of	the	ETA	receptor	onto	the	
corresponding	domain	of	the	ETB	receptor	renders	the	resulting	chimeric	receptor	sensitive	
to	antagonism	by	BQ123.	
Previous	work	has	 also	 found	 that	 a	part	 of	 the	ETA	 receptor	N-terminal	 domain	 in	 close	
proximity	to	the	first	transmembrane	region	and	a	5	amino	acid	sequence	(140-KLLAG-144)	
are	 important	 elements	 for	 ligand	 binding	 [4].	 Furthermore,	 the	 C-terminal	 8–amino	 acid	
residues	located	in	close	proximity	to	the	seventh	transmembrane	region	and	the	C-terminal	
16–amino	acid	residues	in	the	third	intracellular	loop	are	important	for	the	binding	of	ET-1.	
These	 seem	 to	 contribute	 to	 the	 three-dimensional	 structure	 of	 the	 ligand-binding	 site	
located	in	the	extracellular	domains.		
Based	 on	 our	 understanding	 of	 ET-1	 binding	 to	 its	 receptors,	we	 have	 constructed	 fusion	
polypeptides	encompassing	 the	different	ETA	 receptor	 ligand	binding	domains	 (LBDs).	We	
have	 chosen	 to	 proceed	 with	 the	 ETA	 receptor	 LBDs,	 because	 they	 exhibit	 the	 highest	
specificity	to	ET-1	over	its	isoforms.	Phage–display	experiments	(Figure	1)	have	been	used	to	
investigate	the	binding	potential	of	these	different	fusion	polypeptides,	as	described	in	this	
paper.	Phage	display	is	one	of	the	most	powerful	and	widely	used	laboratory	techniques	for	
the	study	of	protein-protein,	protein-peptide	and	protein-DNA	interactions.	This	technology	
is	 mainly	 based	 on	 displaying	 the	 protein	 or	 peptide	of	 interest,	 which	 in	 this	 case	 is	
endothelin-1.	
#Figure	1	
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Methods		
Cloning	and	phage	production	
ETA	 receptor	 LBD	 constructs	 were	 ordered	 as	 synthetic	 DNA	 (Genscript,	 Piscataway,	 NJ,	
USA)	and	cloned	with	SfiI-sites	into	a	phagemid	vector	pHB32x,	which	is	a	modified	vector	of	
pEB32x	containing	a	loxP	site	after	the	truncated	p3-gene	[9].	The	constructs	were	verified	
by	 sequencing	 and	 transformed	 into	 E.	 coli	 strain	 SS320	 for	 phage	 production.	 The	 cells	
were	 grown	 in	 5 ml	 super	 broth	 medium	 (SB)	 containing	 25 μg/ml chloramphenicol	 and	
10 μg/ml	 tetracycline	 at	 37	 °C	 with	 250	 rpm	 shaking	 to	mid-log	 phase	 and	 infected	with	
helper	 phage	 VCSM13	 for	 1	 h	 at	 37	 °C.	 	 Kanamycin	 was	 added	 to	 a	 final	 50	 µg/ml	
concentration	and	the	cultures	were	grown	over	night	at	30	°C	with	250	rpm	shaking.		Phage	
stocks	were	prepared	with	two	sequential	PEG/NaCl-precipitations	according	to	a	standard	
protocol	to	a	final	volume	of	500	µl	PBS.	Phage	titers	were	determined	by	quantitative	PCR,	
targeting	 the	 truncated	 p3-gene	 using	 previously	 titered	 phage	 stock	 pHB32x-SpyC	 as	 a	
standard.	
The	5	different	constructs	ordered	from	Genscript	are	designated	ETtr1-5.	These	constructs	
vary	 in	 the	 combination	of	 LBDs	 that	 constitute	each	 fusion	polypeptide	 (see	Figure	3	 for	
details	 of	 LBDs	 in	 each	 construct);	 the	 fusions	 are	 connected	 by	 an	 EAAAK	 amino	 acid	
sequence.	
Phage	immunoassay	
Anti-HA	 phage	 immunoassays	 were	 performed	 by	 diluting	 5x109	 cfu	 phage	 from	 each	
display	stock	in	500	µl	phosphate	buffered	saline	tween	(PBST	0.05)	+	1%	w/v	bovine	serum	
albumin	 (BSA).	All	 incubations	were	performed	at	 room	 temperature.	 The	phage	 samples	
were	mixed	 with	 100	 µg	 of	 prewashed	 paramagnetic	 Dynabeads	MyOne	 Streptavidin	 C1	
(Invitrogen)	to	analyse	nonspecific	background	binding.	The	phage	samples	were	also	mixed	
with	 100	 µg	 Pierce	 Anti-HA	Magnetic	 Beads	 (Thermo	 Scientific)	 for	 displayed	 HA-epitope	
detection.	ET-1	phage	 immunoassays	were	performed	by	diluting	2.5x1010	cfu	phage	 from	
each	display	stock	in	500	µl	PBST0.05	+	1%	w/v	BSA	and	mixed	with	100	µg	MyOne	beads	
pre-coated	with	biotinylated	ET-1	(Phoenix	Pharmaceuticals).	Biotinylated	ET-1	was	coated	
at	50	ng/µl	concentration	on	1800	µg	MyOne	Dynabeads	for	30	min,	mixed	by	rotation,	and	
washed	 three	 times	with	1	ml	PBST0.1	before	 the	binding	assay.	 Phages	were	allowed	 to	
	 	 Creating	a	soluble	binder	to	ET-1	 	
5	
	
bind	for	30	min	and	60	min	in	the	anti-HA	and	ET-1	binding	assays,	respectively,	and	washed	
twice	 with	 1	 ml	 PBST0.1.	 The	 bound	 phages	 were	 labelled	 with	 100	 µl	 1/1000	 diluted	
horseradish	 peroxidase	 (HRP)/anti-M13	monoclonal	 conjugate	 in	 PBST0.05	 +	 3%	w/v	 fat-
free	milk	 powder	 for	 30	min	 whilst	 being	 rotated.	 Beads	 were	 washed	 three	 times	 with	
PBST0.1	 and	 transferred	 to	 PCR	 strips.	 Bead	 pellets	 were	 resuspended	 in	 100	 µl	 TMB	
substrate,	vortexed	and	incubated	for	3	min	to	let	the	colour	develop.	Beads	were	collected	
on	a	magnet	and	supernatants	transferred	into	a	transparent	96-well	plate	containing	100	µl	
1	N	H2SO4	to	stop	the	reaction.	The	absorbance	was	measured	at	450	nm	with	SpectraMax	
plate	reader.		
Note:	 Empty	MyOne/anti-HA	 beads	 and	 unrelated	 (HA-)	 pHB32x-SpyCatcher	 phage	 stock	
were	included	as	negative	controls.	
Creating	an	Fc-fusion	construct	and	measuring	binding	affinity	to	ET-1	
The	gene	for	the	fusion	protein	was	designed	and	optimised	for	expression	 in	mammalian	
cells	(HEK293)	prior	to	being	synthesised.	The	sequence	was	then	subcloned	into	a	cloning	
and	expression	vector	for	human	Fc	fusion	proteins.		
The	Fc	constructs	were	generated	using	the	services	of	Absolute	Antibody	Ltd	(Oxford,	UK).	
In	brief,	HEK293	cells	were	passaged	to	the	optimum	stage	for	transient	transfection.	Cells	
were	 transiently	 transfected	 with	 the	 appropriate	 expression	 vector	 and	 cultured	 for	 a	
further	6-14	days.	An	appropriate	volume	of	cells	was	transfected	with	the	aim	of	obtaining	
1-5	mg	of	 purified	 Fc	 fusion	protein.	 Cultures	were	harvested	 and	a	one-step	purification	
performed	using	affinity	chromatography.		
For	this,	culture	supernatant	containing	Fc	fusion	protein	was	loaded	onto	a	MabSelect	SuRe	
Protein	A	column	at	4	ml/min	and	washed	with	phosphate	buffered	saline	(PBS)	pH	7.2.	A	
step	elution	was	performed	with	sodium	citrate	pH	3.0	buffer.	Eluted	protein	was	
neutralised	with	10%	(v/v)	Tris	pH	9.0.	Upon	successful	purification,	the	Fc	fusion	protein	
was	buffer	exchanged	into	PBS	pH	7.4.	The	protein	was	analysed	for	purity	by	SDS-PAGE	and	
concentration	determined	by	UV	spectroscopy	(at	280	nm).		
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For	the	binding	affinity	measurement,	we	employed	the	use	of	the	Octet	Red96	system	[10].	
For	this,	we	fixed	biotinylated	ET-1	(Phoenix	Pharmaceuticals)	and	then	probed	with	our	Fc-
fusion	construct.	
Binding	affinity	measurement	
The	kinetics	of	Fc-ETtr1	and	Fc-ETtr2	binding	to	biotinylated-endothelin-1	was	determined	
using	 the	 Octet	 Red96	 system	 (ForteBio,	Menlo	 Park,	 CA).	 The	 buffer	 for	 the	 assays	was	
phosphate	buffered	saline	(PBS)	with	0.01%	(w/v)	bovine	serum	albumin	(BSA)	and	0.002%	
Tween-20.	 The	 measurements	 were	 carried	 out	 at	 30	 °C.	 1	 µg/ml	 bio-endothelin-1	 was	
captured	on	dip-and-read	STR	(streptavidin)	sensors,	followed	by	binding	of	Fc-ETtr1	and	Fc-
ETtr2	at	500	nM	concentration.	The	ForteBio	Octet	analysis	software	(ForteBio,	Menlo	Park,	
CA)	 was	 used	 to	 generate	 the	 sensorgram.	 The	 signal	 from	 an	 endothelin-mounted	 tip	
without	the	Fc-fusion	was	used	as	a	reference	and	subtracted	from	the	sample	signals.		
Statistics	 	
Statistical	 analysis	 was	 performed	 by	 analysis	 of	 variance	 (Fisher’s	 Protected	 Least	
Significant	Difference	test),	with	p	<	0.001	being	considered	significant.	
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Results	
For	 phage	 display,	 the	 endothelin	 binding	 constructs	 were	 cloned	 as	 a	 fusion	 to	 the	
truncated	g3p	 (g3p-CT)	of	 filamentous	phage.	HA	epitope,	YPYDVPDYA,	was	 inserted	 in	all	
display	 constructs	 between	 the	 protein	 of	 interest	 and	 the	 g3p-CT	 to	 assess	 the	 display	
performance.	 The	 HA-epitope	 was	 detected	 on	 all	 phage	 samples	 by	 binding	 5x109	 cfu	
display	 phage	 particles	 on	 anti-HA	 coated	 beads	 indicating	 that	 the	 constructs	 were	
displayed	on	the	phage	coat	(Figure	2).				
#Figure	2	
The	 binding	 of	 the	 ETtr	 constructs	 to	 ET-1	was	 then	 analysed	 on	 streptavidin	 beads	 pre-
coated	to	saturation	with	biotinylated	ET-1;	n=3	(Figure	3).	As	mentioned	in	the	Introduction	
section,	 Phage	display	 is	 a	powerful	 technique	 commonly	used	 today	 to	 identify	different	
protein-protein	interactions.	
#Figure	3	
Of	the	different	peptides	tested,	ETtr1	and	ETtr2	exhibited	statistically	significant	binding	to	
biotinylated	ET-1	as	deduced	from	application	of	an	analysis	of	variance	(Fisher’s	Protected	
Least	Significant	Difference)	test;	n=3,	p=0.0007.	
As	a	next	step,	we	proceeded	to	construct	Fc	fusion	proteins	of	ETtr1	and	ETtr2.	SDS-PAGE	
analysis	 confirmed	 that	both	 constructs	were	 successfully	 expressed	as	 identified	by	 their	
respective	molecular	weights:	93.7kDa	for	ETtr1	and	88.9kDA	for	ETtr2	(Figure	4).		
#Figure	4	
Both	constructs	were	expressed	and	isolated	with	a	purity	of	>98%.	Using	these	constructs,	
we	then	proceeded	to	analyse	the	binding	affinity	of	each	soluble	construct.	The	first	set	of	
binding	experiments	did	not	exhibit	any	binding	to	bioendothelin-1	with	either	Fc-ETtr1	or	
Fc-ETtr2	(Figure	5A	and	B).		
#Figure	5A	and	B	
We	did	not	observe	any	binding	of	either	dimeric	Fc-fusion	construct	(Fc-ETtr1	or	Fc-ETtr2).	
This	was	despite	the	strong	binding	obtained	in	our	phage	experiments	(Figure	3).	It	is	likely	
that	 the	 unpaired	 cysteine	 residues	 in	 each	 arm	 of	 our	 construct	 cross-link	 to	 form	
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disulphide	bridges	that	conceal	the	ligand-binding	site	in	such	a	way	that	we	do	not	observe	
any	 ET-1	 binding.	 Breaking	 these	 disulphide	 linkages	 with	 a	 mild	treatment	 of	 DTT,	 did	
restore	ET-1	binding	of	our	constructs	(Figure	6A	and	B).		
	
#Figure	6A	and	B	
	
The	 binding	assay	 revealed	 a	 strong	 binding	 of	 the	 monomeric	 Fc-ETtr1	 construct;	 mean	
binding	affinity	of	21.2	nM	(n=6;	see	table	1).	The	binding	affinity	of	the	monomeric	Fc-ETtr2	
construct	was	found	to	be	weaker	at	77.3	nM	(n=3;	KD	error	=	1.567E-09).	It	is	important	to	
note	 that	any	effects	of	DTT	were	controlled	by	use	of	 just	 ‘buffer	+	DTT’,	which	gave	no	
binding	 to	 ET-1.	 The	 signal	 recorded	 for	 each	 monomeric	 Fc-ETtr	 construct	 is	 with	
subtraction	of	the	corresponding	control,	i.e.	‘buffer	+	DTT’.		
	
Table	1.	Binding	data	for	the	monomeric	Fc-ETtr1	construct.		
	
The	 binding	assay	 revealed	 a	 strong	 binding	 of	 the	monomeric	 Fc-ETtr1	 construct;	mean	 binding	 affinity	 of	
2.120	X	10-8	M,	i.e.	21.2	nM	(n=6).	
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Discussion	
In	this	study,	we	constructed	fusion	polypeptides	encompassing	the	different	ETA	receptor	
ligand	binding	domains,	which	exhibited	the	highest	specificity	to	ET-1	over	its	isoforms,	i.e.	
ET-2	and	ET-3.	We	connected	the	different	ETA	receptor	LBDs	using	rigid	linkers,	which	are	
alpha	 helix-forming	 linkers	 with	 the	 sequence	 of	 (EAAAK)n.	 As	 has	 been	 previously	
suggested,	many	natural	linkers	exhibit	α-helical	structures,	which	are	rigid	and	stable,	with	
intra-segment	hydrogen	bonds	and	a	closely	packed	backbone	[11,	12].	Therefore,	the	stiff	
α-helical	 linkers	may	act	as	rigid	spacers	between	protein	domains,	which	would	allow	the	
ETA	 receptor	 extracellular	 loops	 (ECLs)	 to	 retain	 their	 structure	 to	 a	 higher	 degree	 once	
dissociated	from	their	natural	configuration	as	a	part	of	a	GPCR.		
We	 used	 'EAAAK'	 linkers	 before	 and	 after	 the	 ECL	 domains,	 because	 the	 ET	 receptor	
extracellular	 loops	 needed	 to	 be	 between	 helices,	 as	 suggested	 in	 the	 previous	 study	 by	
Orry	 and	Wallace	 (2000),	 which	 produced	 a	 model	 of	 the	 ETA	 receptor	 and	 ET-1	 ligand	
binding	this	GPCR	[13].		
Our	 results	 show	 that	 constructs	 ETtr1	 and	 ETtr2	 give	 statistically	 significant	 binding	 to	
biotinylated	 ET-1.	 	 Constructs	 ETtr1	 and	 ETtr2	 contain	 ICL3	 (16	 amino	 acids)	 and	 the	 C-
terminus	(8	amino	acids)	domains,	which	are	lacking	in	construct	ETtr4	and	ETtr5.	Therefore,	
either	one	or	both	of	 these	domains	are	 important	 for	ET-1	binding.	Furthermore,	ECL2	 is	
lacking	 in	ETtr3	 (which	gave	only	very	weak	binding	to	biotinylated	ET-1)	but	 is	present	 in	
ETtr1	and	ETtr2	(Figure	3).	Hence,	 the	ECL2	domain	also	appears	to	be	 important	 for	ET-1	
binding.	
As	 a	 next	 step,	we	 created	 Fc-fusion	 constructs	 of	 ETtr1	 and	 ETtr2	 (that	 gave	 statistically	
significant	 binding	 to	 biotinylated	 ET-1	 in	 our	 phage	 experiments).	 The	 binding	 affinity	 of	
these	 constructs	 to	 ET-1	 was	 then	 measured,	 as	 the	 Fc-fusion	 construct	 is	 what	 may	
eventually	be	used	as	a	drug.	Fc-fusion	proteins	form	an	important	class	of	therapeutics	as	
evinced	by	the	successful	application	of	cytokine	traps	for	patients	with	rheumatoid	arthritis	
and	 other	 autoimmune	 disorders	 [14,	 15].	 Our	 study	 confirmed	 the	 solubility	 of	 our	
constructs	 and	 revealed	a	 strong	binding	affinity	of	21.2	nM	 (n=6)	 for	 the	monomeric	 Fc-
ETtr1	construct.	
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Interestingly,	 ETtr1	 gave	 stronger	 binding	 than	 the	 ETtr2	 construct.	 This	 highlights	 the	
importance	 of	 the	 third	 extracellular	 loop	 domain	 (D-loop),	which	 is	 present	 in	 ETtr1	 but	
absent	 from	ETtr2.	Previous	research	has	shown	that	both	the	C-	and	D-	 loops	of	 the	ETA	
receptor	are	responsible	for	ligand	(ET-1)	selection	[4].	
	
Next	 steps	 in	 our	 project	 include	 the	 current	 development	 of	 a	 monomeric	 Fc-ETtr1	
construct	 (in	 order	 to	 circumvent	 use	of	DTT	 to	 generate	monomers	 from	our	 dimeric	 Fc	
construct),	followed	by	characterisation	of	its	binding	affinity.	This	would	confirm	that	cross-
linking	of	cysteine	residues	in	our	current	dimeric	Fc	construct	is	an	issue	for	ligand	binding.	
Alternative	designs	for	creating	Fc	constructs	are	detailed	in	Figure	7.	These	formats	would	
circumvent	any	 issues	of	 cross-linking	of	 cysteine	 residues,	 as	was	observed	earlier	 in	our	
study.	
#Figure	7	
Fcγ	 recombinant	 forms	 a	 group	 of	 recombinant	 proteins	 called	 Fc-fusion	 proteins	 (FFPs).	
Our	 ET-traps	 are	 also	 an	 Fc-fusion	 protein.	 FFPs	 are	 widely	 used	 in	 drug	 discovery,	 drug	
delivery,	vaccine	design	and	experimental	 research	on	 receptor–ligand	 interactions.	These	
fusion	 proteins	 have	 become	 successful	 alternatives	 to	 monoclonal	 antibodies	 for	 drug	
developments	 [16].	 In	all,	 “the	customizable	 functionality	of	FFPs	creates	advantages	over	
antibody-based	therapies	by	combining	modular	building	blocks	that	can	reach	targets	not	
accessible	 to	 antibodies.	 Additional	 advantages	 include	 lower	 patient	 dosing,	 reduced	
production	 costs,	 and	 improved	 product	 homogeneity”	 (PEGS	 Boston,	 April	 2016).	
Therefore,	our	Fc-fusion	ET-trap	may	provide	a	novel	therapeutic	tool,	which	remains	to	be	
tested	in	the	next	phase	of	this	project.	
In	 summary,	 we	 have	 developed	 a	 soluble	 binder	 to	 our	 target	 ligand	 (ET-1),	 which	 in	
physiology	binds	a	GPCR.	These	constructs	consist	of	different	peptide	sequences	that	have	
been	identified	as	strong	binders	to	our	target	ligand	(based	on	previous	research).	To	our	
knowledge,	we	are	the	first	to	have	reported	the	development	of	a	soluble	form	of	a	GPCR	
in	 terms	 of	 its	 ligand	 binding	 ability.	 Although	 our	 study	 was	 based	 on	 ET-1,	 the	 same	
strategy	may	be	applied	to	other	GPCR–ligand	systems,	which	may	lead	to	the	discovery	of	
novel	therapeutics	in	different	disease	areas.	
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Importance	+	Future	opportunities	
Thus	 far,	we	have	used	phage	display	experiments	 to	 identify	 strong	binders	 to	 ET-1.	We	
have	also	expressed	the	top-binders	as	Fc-fusion	proteins,	which	confirmed	their	solubility	
and	allowed	us	to	determine	their	binding	affinity.	The	next	steps	 in	our	project	will	be	to	
apply	affinity	maturation	to	our	constructs	 to	 further	 improve	 its	binding	affinity	 for	ET-1.	
We	 also	 intend	 to	 investigate	 the	 possibility	 of	 using	 the	 ETB	 receptor	 ligand	 binding	
domains	 for	 construction	 of	 ET-traps.	 Previous	 studies	 have	 found	 that	 the	 ETB	 receptor	
strongly	binds	ET-1	but	without	specificity	over	its	isoforms	as	found	with	the	ETA	receptor	
[17].	Hence,	we	would	aim	to	develop	a	combination	fusion	polypeptide	that	encompasses	
both	the	strong	ligand	binding	ETB	receptor	domains,	as	well	as	the	ET-1-ligand	specific	ETA	
receptor	domains.		
Our	 aim	will	 be	 to	 test	 the	 efficacy	 of	 this	 construct	 as	 a	 therapeutic	 tool.	We	 intend	 to	
investigate	the	therapeutic	effects	of	ET-traps	in	pre-eclampsia	disease.	Extensive	research	
has	implicated	the	vasoactive	peptide,	ET-1,	as	a	major	pathological	factor	in	pre-eclampsia	
[18-21].	Clinical	data	have	confirmed	that	ET-1	levels	are	significantly	elevated	in	the	blood	
of	women	with	pre-eclampsia.	ET-1	levels	have	been	found	to	be	almost	ten	times	higher	at	
35-50pg/ml	 in	 women	 with	 pre-eclampsia	 compared	 with	 5-10pg/ml	 in	 normotensive	
controls	 [18].	 Increased	 ET-1	 has	 also	 been	 shown	 to	 be	 a	 primary	 event	 in	 the	
pathophysiology	 of	 pre-eclampsia,	 being	 a	 stimulus	 of	 inflammation,	 hypertension	 and	
coagulation,	which	are	all	key	characteristics	of	the	disease.	Previous	work	has	shown	that	
different	 markers	 of	 pathology	 are	 reduced	 significantly	 upon	 sequestering	 ET-1	 [21].	 If	
successful	 to	 reach	 the	market,	ET-traps	would	offer	a	 long	overdue	 treatment	option	 for	
pregnancy	disorders,	such	as	pre-eclampsia.	
Elevated	 ET-1	 levels	 are	 also	 implicated	 in	 a	 host	 of	 other	 diseases	 as	 well,	 including	
cardiovascular	 disease	 and	 neurodegenerative	 disorders	 [22].	 Further	 research	 could	 also	
explore	the	efficacy	of	ET-traps	in	these	other	disease	areas.	
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Figure	legends	
Figure	1.	Phage	experiments	strategy	using	biotinylated	endothelin-1	and	endothelin-1	traps	(ETtr).	
Figure	2.	Phage	immunoassay	for	the	detection	of	HA-epitope,	done	for	ETtr1-5.	Negative	control	was	a	phage	
stock	displaying	an	unrelated	protein	(SpyCatcher).	The	assay	was	repeated	3	times	with	replicate	phage	stocks	
with	similar	results.	
Figure	3.	Phage	immunoassay	for	binding	of	ETtr1-5	to	biotinylated	endothelin-1.	The	negative	control	was	a	
phage	 stock	 displaying	 an	 unrelated	 protein	 (SpyCatcher).	 Data	 represent	 the	 mean	 of	 three	 independent	
experiments	with	standard	deviation.	Unspecific	binding	was	analysed	in	parallel	by	 incubating	the	phage	on	
streptavidin	 beads	 without	 any	 coated	 antigen.	 Statistical	 analysis	 was	 performed	 by	 analysis	 of	 variance	
(Fisher’s	Protected	Least	Significant	Difference	test),	with	p	<	0.001	being	considered	significant.	
The	 table	 below	 the	 figure	 illustrates	 what	 LBDs	 of	 the	 ETA	 receptor	 constitute	 (marked	 with	 an	 ‘x’)	 each	
construct.	
Figure	4	(A	and	B).	SDS-PAGE	blots	of	expressed	(A)	ETtr1	and	(B)	ETtr2	constructs.	SDS-PAGE	analysis	of	(A)	Fc-
ETtr1	 and	 (B)	 Fc-ETtr2	 confirmed	 that	 both	 constructs	 were	 expressed;	 identified	 as	 per	 their	 respective	
molecular	weights	 (93.7kDa	 for	ETtr1	and	88.9kDA	 for	ETtr2).	Both	 constructs	were	expressed	with	a	purity	
>98%.	 NR=non-reduced	 and	 R=reduced.	 Non-reduced	 forms	 of	 both	 ETtr1	 and	 ETtr2	 were	 expressed	
sufficiently	to	isolate	5mg	of	each	at	a	concentration	of	1mg/ml.		
Figure	5.	Sensograms	of	(A)	Fc-ETtr1	and	(B)	Fc-ETtr2	binding	to	biotinylated	ET-1.	Representative	plots	shown	
for	each	of	the	two	constructs.	Neither	Fc-ETtr1	nor	Fc-ETtr2	in	the	current	dimer	form	exhibits	any	binding	to	
biotinylated	ET-1	(n=3).		
Figure	6.	Sensograms	of	(A)	Fc-ETtr1	and	(B)	Fc-ETtr2,	binding	to	biotinylated	ET-1.	Representative	plots	shown	
for	each	of	the	two	constructs.	Both	constructs	are	in	monomeric	form	after	a	mild	pre-treatment	with	10mM	
DTT.	ETtr1	gave	a	mean	KD	of	21.2	nM	(n=6)	and	ETtr2	gave	a	mean	KD	of	77.3	nM	(n=3).		
Figure	7.	Possible	formats	of	Fc-fusion	constructs,	with	the	black	circle	being	the	fusion	protein.	
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Figure	5	(A	and	B)	
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Figure	6	(A	and	B)	
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